Key result
Dilevalol effectively reduced blood pressure with a lower overall discontinuation rate than metoprolol and fewer withdrawals due to depression or impotence.
Why the study?
The influence of beta2 agonism combined with beta1 and beta2 antagonism on adverse effects and plasma lipoproteins compared to beta1 selective antagonism was unclear.
RCT (n=449)
Yes
Answers are grounded in this paper and cite their sources.
Dilevalol matches metoprolol for BP control with fewer discontinuations and favorable lipid shifts; extends evidence for beta2 agonism benefits in hypertension.
Dilevalol combines vasodilation due to selective beta 2 agonism and nonselective beta antagonism. We studied 311 patients randomized to dilevalol and 138 to metoprolol in a multicenter trial. After a 4-week placebo washout, dilevalol was titrated from 200 to 1,600 mg once daily and metoprolol from 100 to 400 mg to a goal supine diastolic blood pressure less than 90 and greater than or equal to 10 mm Hg decrease from baseline. Responders were followed for 1 year. The average age of patients was 51 years; 72% were men and 54% were white. Both drugs reduced blood pressure effectively to a similar level. Fewer patients discontinued dilevalol than did those taking metoprolol (9 vs 16%; p less than 0.03). More metoprolol-treated patients withdrew because of depression (6 vs less than 1%; p = 0.03) and impotence (5 vs less than 1%; p = 0.03). Lipoprotein levels before and after treatment were measured in 99 patients treated for 53.5 weeks with dilevalol (mean dose 438 mg). Dilevalol increased high-density lipoprotein (HDL) cholesterol by 2.5 mg/dl to 47.2 (p = 0.05), reduced low-density lipoprotein (LDL) cholesterol by 2.5 mg/dl, increased HDL/LDL by 0.03, and decreased total cholesterol/HDL cholesterol by 0.18. Triglycerides increased by 21 mg/dl (p = 0.06). In patients with an initial HDL cholesterol less than 35 mg/dl, dilevalol increased it by 9 mg/dl. In patients treated with metoprolol, the only significant change (p = 0.02) was a 41.9-mg/dl increase in triglyceride levels.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Materson et al. (1989) conducted an RCT in Hypertension (n=449). Dilevalol vs. Metoprolol (100 to 400 mg) was evaluated on Treatment discontinuation (p=<0.03). Dilevalol effectively reduced blood pressure with a lower overall discontinuation rate than metoprolol and fewer withdrawals due to depression or impotence.
Synapse has enriched 10 related papers. Consider them for comparative context: